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(54) GENE GROUP APPLICABLE TO CANCER PROGNOSTICATION
(57) To provide a novel method for determining the
risk of lymph node metastasis of breast cancer uses as
an index the difference in the expression levels of marker
genes between metastatic breast cancer tissue (or cell)
and non-metastatic breast cancer tissue (or cell). The
method involves (1) measuring the expression level of a
gene having a base sequence in human metastatic
breast cancer tissue (or cell), (2) measuring the expres-
sion level of the same gene in human non-metastatic
breast cancer tissue (or cell), and (3) comparing the ex-
pression level of (1) with the expression level of (2) and
determine the risk of lymph node metastasis of breast
cancer based on the difference between the expression
levels.
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Description
Technical Field
[0001] The present invention relates to a novel method for determining the risk of lymph node metastasis of breast
cancer. More specifically, the present invention relates to a method for determining the risk of lymph node metastasis
of breast cancer that is based on comparison of the expression levels of marker genes having specific base sequences
between metastatic breast cancer cells and non- metastatic breast cancer cells.
Background Art
[0002] In Japan, the number of breast cancer patients is growing rapidly. The cancer is the most prevalent of all
cancers in women. Estrogen, a female hormone, is considered a risk factor of breast cancer: women who have been
exposed to estrogen for a longer period of time due to early menarche, late menopause, late age at first birth or nulliparity
are more likely to develop breast cancer. Western-style high- fat diet and obesity are also associated with this type of
cancer since estrogen is primarily produced in fat tissue in postmenopausal women. The changing lifestyles of Japanese
women, such as their active participation in society, also contribute to the increase in the incidence of breast cancer.
[0003] Breast cancer is generally divided into three classes: non-invasive carcinomas, invasive carcinomas and Paget’s
disease of the breast. Most of the incidences of breast cancer that form lumps are invasive. There are common and
special types of invasive breast cancers. The common types include scirrhoma, papillotubular carcinoma and solid-
tubular carcinoma. The special types include mucinous carcinoma.
[0004] Because no blood test is available to specifically detect breast cancer, the detection of early breast cancers
relies primarily on palpation and X- ray imaging. However, these techniques, even when used in combination, fail to
detect as much as 20% of the cancer. In addition, diagnosis by X-ray imaging often requires specialists. The cytodiagnosis
conducted before and during the surgical procedures can only be done by a pathologist and is often difficult due to the
shortage of experienced pathologists and varying standards of the diagnosis. Thus, no subjective and simple technique
for the detection/diagnosis of early breast cancers has ever existed to bridge the gap between detection and diagnosis
of the disease. The PET analysis, a new diagnostic technique that can detect tumor tissue 1mm or less in diameter,
requires large- scale facilities and is therefore not readily used for the detection of breast cancer.
[0005] Recent studies have shown that cancers are caused by anomalies in genes. For example, techniques have
been proposed that detect cancer cells by making use of the fact that certain genes are expressed at different levels in
a cancer tissue and a normal tissue (Patent Literatures 1 and 2).
[Patent Literature 1] Japanese Patent Application Laid-Open (JP-A) No. 2003-284594
[Patent Literature 2] Japanese Patent Application Laid- Open (JP-A) No. 2003-284596
Disclosure of the Invention
[0006] Once lymph node-metastatic breast cancer has been removed by surgery, prognosis is predicted based on
indices such as tumor size, nuclear pleomorphism of the removed cancer cells and of hormone receptor levels. Where
necessary, adjuvant therapy is given to prevent metastasis to lymph nodes or the recurrence of cancer. The prediction
of prognosis based on these presently available indices is not accurate enough, however, and more accurate indices
for the prognosis of breast cancer patients are therefore needed to reduce the risk of recurrence and improve patients’
quality of life by proper medication.
[0007] In view of the bove-described problems, the present inventors have conducted extensive studies and observed
that certain marker genes are expressed at different levels in metastatic breast cancer cells or tissues and in non-
metastatic breast cancer cells or tissues. The present inventors found that these marker genes could be used to determine
the risk of lymph node metastasis of breast cancer and ultimately devised the present invention. Accordingly, the present
invention provides the following measures to address the above-described problems.
(1) A method for determining the risk of lymph node metastasis of breast cancer, including using as an index the
difference in the expression level of a marker gene between a metastatic breast cancer tissue (or cell) and a non-
metastatic breast cancer tissue (or cell).
(2) The method according to (1) above, wherein the expression level of the marker gene is determined by the amount
of mRNA of the gene.
(3) The method according to (1) or (2) above, wherein the marker gene is at least one selected from the group
consisting of genes having base sequences of GenBank accession Nos. NM000903, NM006804, NM033547,
CR611676, NM177967, NM152558, NM178167, NM003752, AK131568, CR592336, NM178507, NM002862,
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NM006913, NM005794, NM014164, NM000853 and a base sequence extending from 178882962bp to
178883181bp of chromosome 3, and homologs thereof.
(4) The method according to any one of (1) to (3) above, wherein the expression level of the marker gene in the
metastatic breast cancer tissue (or cell) is equal to or higher than twice the expression level in the non- metastatic
breast cancer tissue (cells), or equal to or lower than one- half the expression level in the non- metastatic breast
cancer tissue.
[0008] The method of the present invention enables quick and simple determination of the risk of lymph node metastasis
of breast cancer at the genetic level, thus providing an effective way to prevent metastasis of breast cancer.
Brief Description of the Drawings
[0009]
Fig. 1 is a diagram showing a comparison of the expression levels of a transcript (transcript 1) of a marker gene
according to high-coverage gene expression profiling (HiCEP).
Fig. 2 is a diagram showing a comparison of the expression levels of a transcript (transcript 2) of another marker
gene according to HiCEP.
Fig. 3 is a diagram showing a comparison of the expression levels of a transcript (transcript 3) of another marker
gene according to HiCEP.
Fig. 4 is a diagram showing a comparison of the expression levels of a transcript (transcript 4) of another marker
gene according to HiCEP.
Fig. 5 is a diagram showing a comparison of the expression levels of a transcript (transcript 5) of another marker
gene according to HiCEP.
Fig. 6 is a diagram showing a comparison of the expression levels of a transcript (transcript 6) of another marker
gene according to HiCEP.
Fig. 7 is a diagram showing a comparison of the expression levels of a transcript (transcript 7) of another marker
gene according to HiCEP.
Fig. 8 is a diagram showing a comparison of the expression levels of a transcript (transcript 8) of another marker
gene according to HiCEP.
Fig. 9 is a diagram showing a comparison of the expression levels of a transcript (transcript 9) of another marker
gene according to HiCEP.
Fig. 10 is a diagram showing a comparison of the expression levels of a transcript (transcript 10) of another marker
gene according to HiCEP.
Fig. 11 is a diagram showing a comparison of the expression levels of a transcript (transcript 11) of another marker
gene according to HiCEP.
Fig. 12 is a diagram showing a comparison of the expression levels of a transcript (transcript 12) of another marker
gene according to HiCEP.
Fig. 13 is a diagram showing a comparison of the expression levels of a transcript (transcript 13) of another marker
gene according to HiCEP.
Fig. 14 is a diagram showing a comparison of the expression levels of a transcript (transcript 14) of another marker
gene according to HiCEP.
Fig. 15 is a diagram showing a comparison of the expression levels of a transcript (transcript 15) of another marker
gene according to HiCEP.
Fig. 16 is a diagram showing a comparison of the expression levels of a transcript (transcript 16) of another marker
gene according to HiCEP.
Fig. 17 is a diagram showing a comparison of the expression levels of a transcript (transcript 17) of another marker
gene according to HiCEP.
Best Mode for Carrying Out the Invention
[0010] The present invention concerns a method for determining the risk of lymph node metastasis of breast cancer
that uses as an index of the risk of metastasis the difference in the expression levels of specific marker genes between
metastatic breast cancer cells or tissues and non- metastatic breast cancer cells or tissues. As used herein, the term
"marker gene" refers to a gene that enables the determination of the risk of metastasis of breast cancer cells by comparing
its expression levels between metastatic breast cancer cells or tissues and non-metastatic breast cancer cells or tissues.
[0011] The present invention also concerns a method for determining the risk of lymph node metastasis of breast
cancer in which the expression levels of the marker genes are determined by the amounts of mRNA of the marker genes.
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More specifically, the present invention concerns a method for determining the risk of lymph node metastasis of breast
cancer that involves extracting total RNA from cells obtained from metastatic and non-metastatic breast cancer tissues,
and comparing the amounts of mRNA transcripts transcribed from the marker genes. Different techniques for gene
expression analysis can be used to determine the amounts of mRNA of genes of interest, including comprehensive
transcriptome analysis (high-coverage gene expression profiling, HiCEP), DNA microarrays, quantitative RT-PCR and
northern hybridization. Gene expression analysis techniques that can determine the amounts of mRNA without extracting
total RNA from cells, such as in situ hybridization, may also be used in the present invention. The above-described
techniques may be used in combination to improve the accuracy of detection. The translated products of the genes of
the present invention may also be quantified by, for example, determining the amounts of proteins coded by the genes.
Proteins of interest can be quantified by using techniques such as immunological assays using antibodies specific for
the proteins (such as ELISA, western blotting and RIA), two-dimensional electrophoresis and high-performance liquid
chromatography (HPLC). Antibodies specific for the proteins coded by the genes of the present invention can be prepared
by common techniques using the proteins coded by the genes as antigens.
[0012] HiCEP is one of the transcriptome analysis techniques and is characterized by its comprehensiveness and
high sensitivity. The following is a brief overview of the technique (See Nucleic Acids Res., 2003, Vol. 31, No.16 e94 for
more details): Using common techniques, total RNA is extracted and purified from tissue or cell samples. Double-stranded
cDNA is synthesized from the total RNA using 5’-biotinylated oligo (dT) primers. The cDNA is then digested with a
restriction enzyme MspI. Poly(A)-containing fragments are collected by avidin beads and 3’-adaptor is ligated to the
MspI-digested ends of the collected fragments. The fragments are then digested with a restriction enzyme MseI and 3’-
adapter is ligated to the MseI-digested ends. PCR primers are constructed by adding all possible combinations of two
selected bases to the same adapter sequences as those ligated to 5’ and 3’ ends (16 5’-end primers and 16 3’- end
primers with 5’-end primers fluorescent-labeled). Using these primers, 256 different quantitative PCRs are performed.
The PCR products obtained for each primer pair are loaded on a fragment analyzer to obtain 256 electrophoresis profiles
(gene expression profiles), each containing multiple fluorescence peaks, for a sample. The expression levels of transcripts
can then be compared by comparing the fluorescence peaks among different samples.
[0013] The marker gene for use in the present invention may be any gene that is expressed at significantly different
levels between metastatic breast cancer cells or tissues and non-metastatic breast cancer cells or tissues. For example,
the marker gene may be at least one selected from the group consisting of genes having base sequences of GenBank
accession Nos. NM000903, NM006804, NM033547, CR611676, NM177967, NM152558, NM178167, NM003752,
AK131568, CR592336, NM178507, NM002862, NM006913, NM005794, NM014164 and NM000853 and a base se-
quence extending from 178882962bp to 178883181bp of chromosome 3, and homologs thereof.
[0014] Data stored in the GenBank database may contain the same gene registered by different researchers, at
different times, in different fields and under different names or gene polymorphisms or splicing variants of the same
gene registered as novel genes. Thus, different base sequences that can be considered to be originated from a single
gene may be registered with different accession numbers. These base sequences are collectively referred to as "ho-
mologs." The term is used in the same context throughout this specification.
[0015] One characteristic feature of the method of the present invention for determining the risk of lymph node me-
tastasis of breast cancer is the use of marker genes that are expressed at significantly different expression levels between
metastatic breast cancer cells or tissues and non- metastatic breast cancer cells or tissues. The term "expression level"
may refer to either the amount of mRNA transcribed from a marker gene or the amount of a protein translated from
mRNA. With regard to the difference in the expression level of a marker gene between metastatic breast cancer cells
or tissues and non- metastatic breast cancer cells or tissues, the ratio of the expression level of a marker gene in non-
metastatic breast cancer cells or tissues to the expression level of the same gene in metastatic breast cancer cells or
tissues is preferably in the range of 1.5 or higher or 2/3 or lower, and more preferably in the range of 2 or higher or 1/2
or lower. A marker gene does not serve as an accurate index of the risk of lymph node metastasis of breast cancer and
is therefore not desirable when the ratio of its expression level in non-metastatic breast cancer cells or tissues to that
in metastatic breast cancer cells or tissues is outside the above- described range.
[0016] While the method of the present invention can be applied to any type of breast cancer, including breast ductal
carcinomas (such as papillotubular carcinoma, solid-tubular carcinoma and scirrhoma), lobular carcinomas, special-type
carcinomas (such as mucinous carcinoma, medullary carcinoma and tubular carcinoma) and Paget’s disease of the
breast, it is preferably applied to scirrhoma, lobular carcinomas or solid- tubular carcinoma.
Example
[0017] The present invention will now be described with reference to Examole, which is not intended to limit the scope
of the invention in any way.
[0018] In this Example, the expression levels (RNA transcription levels) of different genes are compared between
human metastatic breast cancer tissue and non-metastatic tissue using one of the gene expression analysis techniques
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known as high- coverage gene expression profiling technique (HiCEP), a known comprehensive, highly sensitive tech-
nique for transcriptome analysis (Nucleic Acids Res., 2003, vol.31 (16), e94).
[0019] The breast cancer tissues used in Example were shown in Table 1. The tissues were collected from five stage
II breast cancer patients (commercial products, all Caucasian, primary tumor, lymph node metastasis (2), no lymph node
metastasis (3), all had stage II cancer based on TNM classification).
[0020] Total RNA was extracted from the samples by a common kit technique using RNeasy kit (Qiagen). 0.1Pg of
total RNA from each sample was used as template and reverse-transcribed using Super Script First Strand Synthesis
System for RT- PCR (Invitrogen). The reverse transcript was incubated with DNA polymerase I (80 units), RNAase H (4
units, Invitrogen) and E. coli DNA ligase (40 units, Invitrogen) at 16°C for 2 hours. The resulting double- stranded DNA
was incubated with restriction enzymes Mse I (40 units, New England Biolabs) and Msp I (50 units, TaKaRa Bio) at 37°C
for 4 hours. Adaptor sequences were ligated to the ends of the resulting DNA fragments. Selective PCRs were performed
using the adaptor-ligated DNA fragments as templates. The amplified products were analyzed by capillary electrophore-
sis. The waveform data were used to determine gene expression levels, compare the gene expression levels among
the samples, and classify the genes into different expression patterns to obtain data for clustering (expression variation
peaks).
[0021] The results of the analysis shown in Table 2 and Figs. 1 through 17 demonstrate that the difference in the
fluorescence peak intensity between samples obtained from patients with lymph node metastasis and samples obtained
from patients with no metastasis was significant for each of the 17 marker gene transcripts. In this analysis, each sample
was assayed in two replicates and the resulting fluorescence peaks were overlapped. Arrows indicate the peaks for the
marker gene transcripts.
[0022] Specifically, Transcripts 1 through 11 (as numbered in Table 1) each show a significant fluorescence peak in
each of the metastasis samples but show no expression peak or, if any, a peak intensity that is half or less of the peak
intensity of the metastasis samples in each of the non-metastasis samples. Conversely, Transcripts 12 through 17 each
show a significant fluorescence peak in each of the non-metastasis samples but show no expression peak or, if any, a
peak intensity that is half or less of the peak intensity of the non-metastasis samples in each of the metastasis samples.
These observations demonstrate that each of the 17 genes can serve as an index of the risk of breast cancer metastasis
that allows the determination of the risk of metastasis based on their expression levels.
Table 1
Samples Metastasis Tumor size Age
#A + 12cm 57
#B + 2cm x 1.5cm x 1.5cm 69
#C - 2.5cm 50
#D - 4cm x 2cm x 1.7cm 61
#E - 6cm x 5.5cm x 4.5cm 68
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Table 2. Transcripts as markers for breast cancer metastasis
Transcripts Sequences GenBank 
Accession No.
Annotation Characteristics
#1 Transcript sequence containing a 
base sequence from 
68302490bp to 68317861bp of (-) 
strand of chromosome 16
NM_000903 NAD(P)H menadione 
oxidoreductase 1
Experssion enhanced 
in metastatic breast 
cancer
#2 Transcript sequence containing a 
base sequence from 
178882962bp to 178883181bp of 
(+) strand
N/A N/A
#3 Transcript sequence containing a 
base sequence from 
35050592bp to 35050643bp of 
(+) strand of chromosome 17
NM_006804 steroidogenic acute 
regulatory protein 
related
#4 Transcript sequence containing a 
base sequence from 
77267542bp to 77272569bp of (-) 
strand of chromosome 11
NM_033547 Homo sapiens 
hypothetical gene 
MGC16733 similar to 
CG12113 
(MGC16733), mRNA.
#5 Transcript sequence containing a 
base sequence from 
176665540bp to 176666255bp of 
(+) strand of chromosome 5
CR611676 Similar to Pxl9- like 
protein (25 kDa protein 
of relevant 
evolutionary and 
lymphoid interest) 
(PRELI) (CGI-106) 
(SBBI12)
#6 Transcript sequence containing a 
base sequence from 
98835662bp to 98835862bp of 
(+) strand of chromosome 13
NM_177967 Phosphoglycerate 
dehydrogenase like 1
#7 Transcript sequence containing a 
base sequence from 2426581bp 
to 2426860bp of(+) strand of 
chromosome 7
NM_152558 IQ motif containing E 
(IQCE)
#8 Transcript sequence containing a 
base sequence from 1987788 bp 
to 1987865 bp of (-) strand of 
chromosome 16
NM_178167 Zinc finger protein 598
#9 Transcript sequence containing a 
base sequence from 228320033 
bp to 28320077 bp of (-) strand of 
chromosome 16
NM_003752 Eukaryotic translation 
initiation factor 3, 
subunit 8, 110kDa
#10 Transcript sequence containing a 
base sequence from 35135544 
bp to 35135831 bp of (+) strand 
of chromosome 17
AK131568 V- erb-b2 
erythroblastic 
leukemia viral 
oncogene homolog 2, 
neuro/ glioblastoma 
derived oncogene 
homolog (avian)
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Industrial Applicability
[0023] Genes according to the present invention enable the highly sensitive and subjective, yet simple and quick
determination of lymph node metastasis of breast cancer, a task that has never been achieved by any of the conventional
techniques. The genes of the present invention therefore serve as markers for the prognosis of breast cancer.
Claims
1. A method for determining the risk of lymph node metastasis of breast cancer, comprising: using as an index the
difference in the expression level of a marker gene between a metastatic breast cancer tissue (or cell) and a non-
metastatic breast cancer tissue (or cell).
2. The method according to claim 1, wherein the expression level of the marker gene is determined by the amount of
mRNA of the gene.
3. The method according to claim 1 or 2, wherein the marker gene is at least one selected from the group consisting
of genes having base sequences of GenBank accession Nos. NM000903, NM006804, NM033547, CR611676,
NM177967, NM152558, NM178167, NM003752, AK131568, CR592336, NM178507, NM002862, NM006913,
(continued)
Transcripts Sequences GenBank 
Accession No.
Annotation Characteristics
#11 Transcript sequence containing a 
base sequence from 35126382 
bp to 35127393 bp of (+) strand 
of chromosome 17
CR592336 V-erb-b2 
erythroblastic 
leukemia viral 
oncogene homolog 2, 
neuro/ glioblastoma 
derived oncogene 
homolog (avian)
#12 Transcript sequence containing a 
base sequence from 119605680 
bp to 119605847 bp of (+) strand 
of chromosome 11
NM_178507 NS5ATP13TP2 
protein
Expression decreased 
in metastatic breast 
cancer
#13 Transcript sequence containing a 
base sequence from 25226174 
bp to 25226624 bp of (+) strand 
of chromosome 20
NM_002862 Phosphorylase, 
glycogen; brain
#14 Transcript sequence containing a 
base sequence from 32256007 
bp to 32256297 bp of (+) strand 
of chromosome 6
NM_006913 Ring finger protein 5
#15 Transcript sequence containing a 
base sequence from 23183541 
bp to 23184510 bp of (-) strand of 
chromosome 14
NM_005794 Dehydrogenase/reduc 
tase (SDR family) 
member 2
#16 Transcript sequence containing a 
base sequence from 40352503 
bp to 40352595 bp of (+) strand 
of chromosome 19
NM_014164 FXYD domain 
containing ion 
transport regulator 5
#17 Transcript sequence containing a 
base sequence from 22700873 
bp to 22700983 bp of (+) strand 
of chromosome 22
NM_000853 Glutathione S-
transferase theta 1
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NM005794, NM014164, NM000853 and a base sequence extending from 178882962bp to 178883181bp of chro-
mosome 3, and homologs thereof.
4. The method according to any of claims 1 to 3, wherein the expression level of the marker gene in the metastatic
breast cancer tissue (or cell) is equal to or higher than twice the expression level in the non- metastatic breast cancer
tissue (cells), or equal to or lower than one- half the expression level in the non- metastatic breast cancer tissue.
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